Antares Pharma Inc

Antares Pharma — Investor Presentation (May 2007)

30 slides from Antares Pharma's investor presentation, May 10, 2007

  1. Slide 1: Antares Pharma, Inc.

    AMEX: AIS May 2007 Antares Pharma, Inc. Improving Pharmaceuticals Through Advanced Drug Delivery Systems

  2. Slide 2: Safe Harbor Statement

    This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not strictly historical sta

  3. Slide 3: Antares Overview

    Antares Overview WE ARE A LEADING PRODUCT COMPANY WITH : THREE VALIDATED DRUG DELIVERY PLATFORMS MULTIPLE PRODUCTS IN KEY THERAPEUTIC FIELDS GROWING REVENUE STREAM OUR OWN PRODUCT ENTERING PIVOTAL TRIALS SIGNIFICANT DEVELOPMENT PIPELINE GLOBAL PRESENCE / LOCATIONS IN BASEL, SWITZERLAND; EWING, NJ; M

  4. Slide 4: Experienced Management

    Experienced Management Jack E. Stover , President & CEO / Sicor, Gynetics, B. Braun Robert F. Apple , Sr. VP & CFO / InKine Pharmaceuticals Dario N. R. Carrara , PhD, SVP & Managing Director / Permatec Peter L. Sadowski , PhD, VP Device Division James E. Hattersley , VP Corporate Business Developmen

  5. Slide 5: Antares is in the "Sweet Spot"

    Antares is in the “Sweet Spot” WE PROVIDE: DIFFERENTIATION IN THE NEW GENERIC- BIOLOGICS MARKETPLACE NOVELTY AND PATENTS FOR EXISTING DRUGS COST EFFECTIVE AT-HOME PATIENT SYSTEMS LOWER EFFECTIVE DOSE AND SAFETY WHICH THE FDA REQUIRES

  6. Slide 6: Areas of Therapeutic Focus

    AREAS OF THERAPEUTIC FOCUS WOMENS’ HEALTH / UROLOGY CENTRAL NERVOUS SYSTEM (CNS) GENERIC BIOLOGICS

  7. Slide 7: Long Term Growth Strategy

    Long Term Growth Strategy USING OUR VALIDATED TECHNOLOGIES WE WILL: Develop products with our partners’ active ingredients in our delivery systems Utilize device division near-term revenues to support longer term product development Develop and commercialize our own niche products

  8. Slide 8: Validated Drug Delivery Platforms

    Validated Drug Delivery Platforms 1. Transdermal ATD ™ Gel Technologies Advanced Transdermal Delivery (ATD TM ) Systemic Compatible with single or multiple actives 3. Fast Melt Tablet Technologies EasyTec™ Orally Disintegrating Tablets 2. Injection Devices Vision / Valeo Needle-free Reusable Injecti

  9. Slide 9: Product Pipeline

    Available Alprazolam ATD™ (anxiety / panic disorder) Testosterone ATD™ (FSD) BioSante (US), EU Available Product Pipeline Easy TEC ™ (ODT) Ibuprofen (pain) Launched Licensed for hGH and Insulin Medi-Jector VISION® / VALEO™ (insulin, hGH) EU Launch Available Nestorone ATD™ (contraception) Available L

  10. Slide 10: Partnered Products

    PARTNERED PRODUCTS

  11. Slide 11: Partner logos

    PHARMACEUTICALS, % BRADLEY PHARMACEUTICALS, INC. XJCR 14> Population Counci “Antares Pharma, Ine @2007

  12. Slide 12: Elestrin Market and Opportunity

    Elestrin ™ Market and Opportunity MARKET MOVING TO TOPICALS Transdermal estrogen products won 15.5% of the $1.9 billion market (up 8.8% since 2002) 45 million American women currently in menopause One dose of Elestrin is 50% lower than the next lowest dose Compliance and ease of application: Elestri

  13. Slide 13: Elestrin Commercial Partnership

    Elestrin ™ Commercial Partnership ATD ™ Gel Drug Delivery Platform Bradley signs as marketing partner Up to $13 million in milestones Payments of $2.6 million received Royalty payments upon commercialization Bradley sales force of 70 specialty reps Antares has the sole rights in Europe and elsewhere

  14. Slide 14: Low-Dose Testosterone for Women

    Low-Dose Testosterone for Women ATD ™ Gel Phase II Study showed 238% increase in satisfying sexual events Phase III currently underway in US with BioSante, our licensee Antares has rights to all clinical data and marketing rights in EU P & G has received approval and launched their FSD product Intri

  15. Slide 15: Teva Commercial Agreements

    TEVA Commercial Agreements Three development and supply agreements to date Teva actives (biologic, generic & branded generic) in our novel delivery systems Attractive economic terms for AIS Upfronts, milestones, device sales & royalties Products anticipated to launch over the next three years Produc

  16. Slide 16: Basis of Our Teva Agreements

    BASIS OF OUR TEVA AGREEMENTS Rapid injection Elimination of sharps disposal High quality subcutaneous injection Interferons,Oncology, MS,Therapeutic Monoclonal Antibodies, Biogenerics Injection Device Drug Delivery Platform Pipeline Opportunities Needle-Free (Reusable) and Mini-Needle (Disposable) A

  17. Slide 17: Joint Development with Population Council

    JOINT DEVELOPMENT WITH POPULATION COUNCIL UNIQUE ATD ™GEL CONTRACEPTIVE Phase I scheduled to begin soon 24- 48 hour sustained release contraceptive in our ATD ™ gel Using API acquired from Merck KG Unique combination of products using natural estradiol instead of synthetic estrogen Minimal adverse e

  18. Slide 18: Fast Melt Tablet Drug Delivery Platform

    Fast Melt Tablet Drug Delivery Platform Multi-national pharmaceutical partner Feasibility and development agreement signed November 2006 Opioid analgesic to be delivered via Antares’ proprietary EasyTec (ODT) delivery platform Opportunity for product life cycle extension EASY TEC™ (ODT) Agreement

  19. Slide 19: Antares Pharma

    o> antares pharma

  20. Slide 20: Urological Advisory Board

    UROLOGICAL ADVISORY BOARD Alan J. Wein, MD, PhD- Professor & Chair, Urology /U of P Roger R. Dmochowski, MD- Professor, Urology / Vanderbilt Joseph F. Harryhill, MD, FACS- Asst. Clinical Professor, Urology / U of P Diane K. Newman, RNC, MSN- Co-Director, Penn Center for Continence and Pelvic Health

  21. Slide 21: ATD Oxybutynin Gel: Anturol

    Our innovative Overactive Bladder product will have… Fast onset of therapeutic activity Decreased incidence of systemic AE’s Lower incidence of local/on-site irritation Accurate, improved once-daily dosing More flexibility and discretion than patch U.S. Market Potential: $200 million ATD ™ Oxybutyni

  22. Slide 22: Anturol Phase II Trial: Skin Erythema

    Overall, skin irritation due to the gel is about 1/3 lower than the patch, comparing data from the marketed 3.9mg/d patch. Anturol™ Phase II Trial: Skin Erythema Comparison to OXYTROL Patch

  23. Slide 23: Anturol Phase II Trial: Conclusions

    Dose proportionality across all doses tested Steady state achieved after 3 applications (i.e., 3 days) Efficacy expected to be comparable to marketed products Safety aspects DEO / OXY similar to Oxytrol patch Superior skin tolerance Cmax not higher than oral products Anturol™ Phase II Trial: Conclus

  24. Slide 24: Anturol Gel Delivery Efficacy Compared to Watson Gel

    Anturol Gel Delivery Efficacy Compared to Watson Gel Data from in vitro study 679/06 using excised pig skin (N=3) ANTUROL Gel 3% delivers 2.6-fold higher OXY levels compared to WATSON Gel 4%, despite a 2-fold lower drug dose (0.18 mg/cm ² versus 0.37 mg/cm²) X 2.6 (p=0.02)

  25. Slide 25: Phase III Trial and Timelines

    Design of pivotal trial and dosing protocol reviewed by FDA 180 patients per arm 12 week, multi-center Selected dosing vs. Placebo Clinical endpoint: # of incontinence episodes Scale-up to 500 kg batch size initiated Underway in Q3-2007 ATD patent notice of allowance issued Feb 2007 PHASE III TRIAL

  26. Slide 26: Selected Financial Information

    Selected Financial Information Consolidated Financial Data (In thousands) Cash and investments ............................ $ 7 , 700 $ 2,7 00 Total assets . ………………………………. 11,500 6,200 Total l iabilities ................................ .......... 6 , 500 5,4 00 Total stockholders’ equity ……………… 5,1

  27. Slide 27: AIS Capital Overview

    AIS Capital Overview Market Cap: $82 M** Shares Outstanding: 53 MM* Fully Diluted Shares: 79 MM* Avg Daily Volume (3 m): 238,000** 52-Week Range: $0.86-$1.75* $10 Million Credit Facility *as of 12.31.06 **as of 4.27.07

  28. Slide 28: 2007 Milestones

    2007 Milestones Receipt of additional milestones from Bradley Q1 Initiation of pivotal clinical trials for Anturol ® Q3 Launch of Elestrin™ - royalty stream Q3 Additional partnerships, including Anturol® Q4 Approval of hGH in Needle-Free Injector Q4 Phase I results of Nestorone® contraceptive gel Q4

  29. Slide 29: 2006 Key Accomplishments

    2006 Key Accomplishments FDA approval of Elestrin ™ for HRT / ATD ™ platform validated with this approval Two Teva deals - revenues over the next three years Positive Phase II results for Anturol ™ Population Council contraceptive joint development agreement 510k filed for hGH ODT agreement / Life c

  30. Slide 30: Antares Pharma, Inc.

    AMEX: AIS May 2007 www.antarespharma.com Antares Pharma, Inc. Improving Pharmaceuticals Through Advanced Drug Delivery Systems

Antares Pharma — Investor Presentation (May 2007) on 6ix